Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Pancreatic Cancer Action Network

PharmaDeviceNews Pancreatic Cancer Action Network

Representative image of pancreatic cancer research as Tango Therapeutics’ vopimetostat and Revolution Medicines’ daraxonrasib combination achieves an 82% response rate in a Phase 1/2 trial.

Pharma & Biotech

Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3

by Soujanya Ravi
October 24, 2026
0 Comments

Tango Therapeutics reports 82% response with vopimetostat and daraxonrasib in pancreatic cancer. Explore the trial results and Phase 3 plans.

Read More

Latest news and features

Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3
Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients
Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy
What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research?
Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab
Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial

POPULAR NEWS

Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.

Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

October 24, 2026

Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.

Pharma & Biotech

Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study

October 24, 2026

Representative image of researchers examining Alzheimer’s disease biomarker data as NeuroSense evaluates PrimeC’s multi-target potential in a small exploratory study.

Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

June 26, 2026

Latest business and industry news

Trump-Musk Starshield dispute eases as Ukraine restores drone connectivity after week of military disruption
Trump administration gives California counties 48 hours to verify ballots as election legal battle intensifies
US pulls diplomats from Middle East as intelligence warns of advanced Iranian attack plots
Eni profit doubles to €2.8bn as buyback reaches €3.8bn. Is the cash boom sustainable?
Volvo Cars plunges 24% after SEK3.7bn loss as another 2,500 jobs go

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.